POSEIDON低预后患者每取卵周期累积活产率:9073例真实世界研究
该多中心回顾性队列研究纳入巴西、土耳其和越南2015—2017年9073例首次IVF/ICSI周期患者,按POSEIDON标准分组。POSEIDON患者每取卵周期累积活产率低于正常反应者(33.7% vs 50.6%,P<0.001),且各组间存在差异,差异主要由女性年龄、获卵数、获胚胎数、移植周期数、不孕年限和BMI决定。
要点
- POSEIDON患者累积活产率较正常反应者低约50%(33.7% vs 50.6%)。
- 年轻预期低反应(1a组)累积活产率27.8%,高龄预期低反应(4组)仅12.5%。
- 获卵4—9枚的亚理想反应者累积活产率约为获卵<4枚者的2倍。
核心结论
- POSEIDON患者每取卵周期累积活产率低于正常反应者,差异主要由女性年龄和获卵数决定,反映卵子质量与数量的重要性。
- 数据支持POSEIDON标准用于识别IVF/ICSI低预后患者亚群的 validity。
研究设计与样本
- 多中心基于人群的回顾性队列研究,纳入巴西、土耳其和越南三个生殖中心2015—2017年治疗的9073例患者。
- 研究对象为22—42岁不孕女性,首次IVF/ICSI周期,采用标准卵巢刺激,移植所有新鲜和/或冷冻胚胎直至活产或胚胎用尽。
- 按POSEIDON标准基于女性年龄、窦卵泡计数(AFC)和获卵数 retrospective 分为四组,另设正常反应者对照组(非POSEIDON)。
主要发现
- POSEIDON患者累积活产率低于非POSEIDON患者(33.7% vs 50.6%;P<0.001)。
- 各POSEIDON组累积活产率:1a组(n=212)27.8%,1b组(n=1785)47.8%,2a组(n=293)14.0%,2b组(n=1275)30.5%,3组(n=245)29.4%,4组(n=623)12.5%。
- 在非预期亚理想/低反应者(POSEIDON 1和2组)中,亚理想反应者(获卵4—9枚)累积活产率是低反应者(获卵<4枚)的2倍(P=0.0004)。
- 逻辑回归显示POSEIDON分组、获胚胎数、每患者移植周期数、获卵数、女性年龄、不孕年限和BMI是累积活产率的 relevant 预测因素(P<0.001)。
关键数值与推荐
- POSEIDON分组标准:年轻(<35岁)和高龄(≥35岁)且AFC≥5,非预期低反应(获卵<4枚)或亚理想反应(获卵4—9枚);以及相应年轻和高龄且卵巢储备受损(预期低反应;AFC<5)者。
- 非POSEIDON(正常反应者)为AFC≥5且获卵>9枚者。
- 累积活产率按每取卵周期计算。
临床怎么用
- 临床可依据POSEIDON标准对低预后患者进行分层,重点关注女性年龄和获卵数对累积活产率的影响。
- 对POSEIDON患者应重视早期诊断、预防及探索可能获益的特定干预措施。
局限性
- 研究依赖窦卵泡计数作为患者分类的生物标志物。
- 各研究中心卵巢刺激方案不同,可能影响患者分类。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the cumulative delivery rate (CDR) per aspiration IVF/ICSI cycle in low-prognosis patients as defined by the Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) criteria? SUMMARY ANSWER: The CDR of POSEIDON patients was on average ∼50% lower than in normal responders and varied across POSEIDON groups; differences were primarily determined by female age, number of embryos obtained, number of embryo transfer (ET) cycles per patient, number of oocytes retrieved, duration of infertility, and BMI. WHAT IS KNOWN ALREADY: The POSEIDON criteria aim to underline differences related to a poor or suboptimal treatment outcome in terms of oocyte quality and quantity among patients undergoing IVF/ICSI, and thus, create more homogenous groups for the clinical management of infertility and research. POSEIDON patients are presumed to be at a higher risk of failing to achieve a live birth after IVF/ICSI treatment than normal responders with an adequate ovarian reserve. The CDR per initiated/aspiration cycle after the transfer of all fresh and frozen-thawed/warmed embryos has been suggested to be the critical endpoint that sets these groups apart. However, no multicenter study has yet substantiated the validity of the POSEIDON classification in identifying relevant subpopulations of patients with low-prognosis in IVF/ICSI treatment using real-world data. STUDY DESIGN, SIZE, DURATION: Multicenter population-based retrospective cohort study involving 9073 patients treated in three fertility clinics in Brazil, Turkey and Vietnam between 2015 and 2017. PARTICIPANTS/MATERIALS, SETTING, METHODS: Participants were women with infertility between 22 and 42 years old in their first IVF/ICSI cycle of standard ovarian stimulation whose fresh and/or frozen embryos were transferred until delivery of a live born or until all embryos were used. Patients were retrospectively classified according to the POSEIDON criteria into four groups based on female age, antral follicle count (AFC), and the number of oocytes retrieved or into a control group of normal responders (non-POSEIDON). POSEIDON patients encompassed younger (<35 years) and older (35 years or above) women with an AFC ≥5 and an unexpected poor (<4 retrieved oocytes) or suboptimal (4-9 retrieved oocytes) response to stimulation, and respective younger and older counterparts with an impaired ovarian reserve (i.e. expected poor responders; AFC <5). Non-POSEIDON patients were those with AFC ≥5 and >9 oocytes retrieved. CDR was computed per one aspirated cycle. Logistic regression analysis was carried out to examine the association between patient classification and CDR. MAIN RESULTS AND ROLE OF CHANCE: The CDR was lower in the POSEIDON patients than in the non-POSEIDON patients (33.7% vs 50.6%; P < 0.001) and differed across POSEIDON groups (younger unexpected poor responder [Group 1a; n = 212]: 27.8%, younger unexpected suboptimal responder [Group 1b; n = 1785]: 47.8%, older unexpected poor responder [Group 2a; n = 293]: 14.0%, older unexpected suboptimal responder [Group 2b; n = 1275]: 30.5%, younger expected poor responder [Group 3; n = 245]: 29.4%, and older expected poor responder [Group 4; n = 623]: 12.5%. Among unexpected suboptimal/poor responders (POSEIDON Groups 1 and 2), the CDR was twice as high in suboptimal responders (4-9 oocytes retrieved) as in poor responders (<4 oocytes) (P = 0.0004). Logistic regression analysis revealed that the POSEIDON grouping, number of embryos obtained, number of ET cycles per patient, number of oocytes collected, female age, duration of infertility and BMI were relevant predictors for CDR (P < 0.001). LIMITATIONS, REASONS FOR CAUTION: Our study relied on the antral follicle count as the biomarker used for patient classification. Ovarian stimulation protocols varied across study centers, potentially affecting patient classification. WIDER IMPLICATIONS OF THE FINDINGS: POSEIDON patients exhibit lower CDR per aspirated IVF/ICSI cycle than normal responders; the differences are mainly determined by female age and number of oocytes retrieved, thereby reflecting the importance of oocyte quality and quantity. Our data substantiate the validity of the POSEIDON criteria in identifying relevant subpopulations of patients with low-prognosis in IVF/ICSI treatment. Efforts in terms of early diagnosis, prevention, and identification of specific interventions that might benefit POSEIDON patients are warranted. STUDY FUNDING/COMPETING INTEREST(S): Unrestricted investigator-sponsored study grant (MS200059_0013) from Merck KGaA, Darmstadt, Germany. The funder had no role in study design, data collection, analysis, decision to publish or manuscript preparation. S.C.E. declares receipt of unrestricted research grants from Merck and lecture fees from Merck and Med.E.A. H.Y. declares receipt of payment for lectures from Merck and Ferring. L.N.V. receives speaker fees and conferences from Merck, Merck Sharp and Dohme (MSD) and Ferring and research grants from MSD and Ferring. J.F.C. declares receipt of statistical services fees from ANDROFERT Clinic. T.M.H. received speaker fees and conferences from Merck, MSD and Ferring. P.H. declares receipt of unrestricted research grants from Merck, Ferring, Gedeon Richter and IBSA and lecture fees from Merck, Gedeon Richter and Med.E.A. C.A. declares receipt of unrestricted research grants from Merck and lecture fees from Merck. The remaining authors have no conflicts of interest to disclose. TRIAL REGISTRATION NUMBER: N/A.
引用
- Esteves SC, Yarali H, Vuong LN, et al. Cumulative delivery rate per aspiration IVF/ICSI cycle in POSEIDON patients: a real-world evidence study of 9073 patients. Hum Reprod. 2021. PMID: 34179973. doi:10.1093/humrep/deab152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。